Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 5, Iss. 3, 2016-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Underpowering in randomized trials reporting a sample size calculation

By Vickers A.J.  

Journal of Clinical Epidemiology, Vol. 56, Iss. 8, 2003-08 ,pp. : 717-720

Elsevier

Access to resources Recommend Favorite

Persistence and Discontinuation of Oral Anticoagulant: Remaining Issues Not Addressed by Phase III Clinical Trials

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 5, Iss. 2, 2016-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ticagrelor: from discovery to Phase III clinical trial

By Siller-Matula Jolanta M   Jilma Bernd  

Future Cardiology, Vol. 6, Iss. 6, 2010-11 ,pp. : 753-764

Future Medicine

Access to resources Recommend Favorite

BDNF Val66Met polymorphism is associated with Stage III–IV endometriosis and poor in vitro fertilization outcome

By Zhang Q.Y.   Guan Q.   Wang Y.   Feng X.   Sun W.   Kong F.Y.   Wen J.   Cui W.   Yu Y.   Chen Z.Y.  

Human Reproduction, Vol. 27, Iss. 6, 2012-06 ,pp. : 1668-1675

Oxford University Press

Access to resources Recommend Favorite